Interaction between Simvastatin and Bempedoic acid
Major
Synergy
| ID | DDInter1675 and DDInter176 |
| Interaction | Coadministration with bempedoic acid may increase the plasma concentrations of simvastatin and pravastatin and risk of statin-related myopathy. The mechanism of the interaction has not been reported. |
| Management | When coadministered with bempedoic acid the simvastatin dosage should not exceed 20 mg daily and the pravastatin dosage should not exceed 40 mg daily. Patients should be monitored for the development of statin-related myopathy. Some authorities consider concomitant use with simvastatin at doses greater than 40 mg daily to be contraindicated (UK). In addition, these same authorities consider coadministration of bempedoic acid with a statin contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases. |
| References | |
| Alternative for Simvastatin |
A10B
More
|
| Alternative for Bempedoic acid |
C10A
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.